---
title: "Eli Lilly (LLY) opens a Hims & Hers channel for Zepbound and Foundayo"
canonical_url: https://www.stockexpertai.com/journal/2026-11-06/eli-lilly-lly-opens-a-hims-and-hers-channel-for-zepbound-and-foundayo-05ba78691d29
last_updated: 2026-11-07T04:10:33.513Z
section: "Biotech Brief"
author: "Stock Expert AI Research"
publisher: Stock Expert AI
tickers: LLY
content_type: journal-article
---

# Eli Lilly (LLY) opens a Hims & Hers channel for Zepbound and Foundayo

_Lilly's Nov. 6, 2026 deal with Hims & Hers adds a telehealth route to its obesity drugs, just after a third quarter with revenue of $24.40B and higher full-year guidance._

![Eli Lilly — Journal cover](/public-objects/streetnews/2026-11-06/BIOTECH_BRIEF-cover-1109989e.jpg)
Stock Expert AI data cover: figures from Financial Modeling Prep.
Photo credit and licence on the image

Eli Lilly said on Nov. 6, 2026 that it reached an agreement with Hims & Hers Health to sell its FDA-approved obesity drugs Zepbound and Foundayo through the Hims & Hers telehealth platform at Lilly's regular self-pay prices. It follows a third quarter ended Sept. 30, 2026 in which total company revenue was $24.40B, of which Cardiometabolic Health, the segment that includes Mounjaro and Zepbound, produced $19.76B. Figures are current as of Nov. 6, 2026 and cover that quarter unless stated.

## Key facts

- **Nov. 6, 2026:** Lilly and Hims & Hers announced the agreement. Lilly shares were $1354, down 0.79% on the latest quote, inside a 52-week range of $850.51 to $1453.
- **Oct. 29, 2026:** Lilly reported third-quarter revenue of $24.40B against an analyst estimate of $22.58B (difference +$1.81B). Non-GAAP EPS was $7.48 against an estimate of $5.71 (difference +$1.77). GAAP diluted EPS was $7.22.
- **Third quarter ended Sept. 30, 2026:** revenue rose 38.6% from the year-ago quarter. Net income of $6.45B rose 15.6%.
- **Full-year 2026 guidance (raised):** CFO Lucas Montarce gave revenue guidance of between $91 and $92 billion.
- **Valuation (trailing 12 months):** P/E (price relative to earnings) of 43.83 and market cap of $1.27T.
- **Next earnings:** Feb. 3, 2027, per our data provider. The analyst estimate is EPS of $11.2 and revenue of $24.58B.

## What happened

**The theme: obesity drugs are moving to where patients already are.** GLP-1 drugs, which mimic a gut hormone that curbs appetite, have become the largest growth category in pharma. Access remains a hurdle: on the call, Ilya Yuffa noted "noise around a number of employers opting out of coverage." Companies are building routes that skip some of that friction. These include direct-to-consumer self-pay pricing, telehealth platforms and a daily pill.

**The latest example.** According to Lilly's release, patients who get a prescription from a licensed provider on the Hims & Hers platform can buy Zepbound (an injection) and Foundayo (a daily oral tablet) at the same self-pay prices open to any patient, and have the medicine shipped to their home. The release said Hims & Hers has never offered compounded copies of Lilly's GLP-1s, meaning custom-mixed versions that are not FDA-approved, and has committed not to in the future. Both companies also committed to keeping prescribing decisions with independent providers. Yuffa, who leads Lilly's US business, said the goal is "meeting patients where they already are." Lilly did not disclose financial terms, and our data does not show any.

**The quarter behind it.** Cardiometabolic Health produced $19.76B of the $24.40B in revenue. Oncology contributed $2.60B, Immunology $1.44B and Neuroscience $444.0M. Our data provider lists a year-ago Cardiometabolic figure of $11.34B, but it labels that period Q2 FY2025, so treat the comparison loosely. The United States produced $15.14B of revenue, Europe $4.46B, China $947.0M and Japan $648.0M.

On the call, management said the drivers were volume growth in Mounjaro and Zepbound, the Medicare GLP-1 Bridge program, and strong Mounjaro sales outside the US. The Bridge program is a pilot that gives Medicare patients access to the drugs. Montarce said Q3 revenue was "positively impacted by approximately $900 million" of one-time items, including a $410 million milestone payment tied to the Boehringer agreement and changes in estimates for rebates and discounts. That flatters the revenue beat. He also said about $2 billion of 2026 revenue came from one-time items that management does not expect to recur, which matters for 2027 comparisons. CEO David Ricks said, "we are in the middle of the largest new category expansion in the history of the pharmaceutical industry."

## Why it matters for investors

## Trend over five quarters.

| Quarter ended | Revenue | Gross margin | Operating margin | Net income | Free cash flow |
|---|---|---|---|---|---|
| Sept. 30, 2025 | $17.60B | 82.9% | 47.6% | $5.58B | $8.61B |
| Dec. 31, 2025 | $19.29B | 82.5% | 46.6% | $6.64B | $677.9M |
| Mar. 31, 2026 | $19.80B | 81.9% | 49.4% | $7.40B | $3.01B |
| June 30, 2026 | $22.97B | 85.8% | 54.2% | $7.09B | $7.76B |
| Sept. 30, 2026 | $24.40B | 83.9% | 35.3% | $6.45B | $8.22B |

Revenue rose in every quarter. What changed in the latest one is the operating margin, which fell to 35.3% from 54.2% in the prior quarter while gross margin stayed high. That points to costs below the gross-profit line. On the earnings call, Montarce said the $7.48 non-GAAP EPS included $4.57 per share of acquired in-process R&D charges, meaning purchased drug candidates expensed up front, and that the non-GAAP performance margin was 54.2%. Those charges are consistent with the gap between the two margin measures, but we cannot split the drop by line item from the data provided. Operating cash flow was $11.40B and capital spending $3.18B. The cash-generation numbers (free cash flow is cash from operations minus capital spending) are strong, and buybacks of $377.0M were smaller than in earlier quarters. Dividends were $1.54B.

**Why the Hims & Hers deal fits.** Management said on the call that only a small share of US patients are on these drugs, so the runway is long. A telehealth channel adds another way to reach people, particularly those paying out of pocket. Management also said net price is a headwind in 2027 that it expects volume to more than offset. A self-pay channel does not remove that pressure.

## Valuation versus peers.

| Company | P/E | Net margin |
|---|---|---|
| Eli Lilly (LLY) | 43.83 | 31.9% |
| AbbVie (ABBV) | 49.97 | 15.7% |
| Johnson & Johnson (JNJ) | 41.88 | 16.2% |
| Amgen (AMGN) | 26.49 | 24.1% |
| AstraZeneca (AZN) | 26.11 | 17.7% |

Lilly has the highest net margin in this group and a P/E between AbbVie and Johnson & Johnson. Its price-to-free-cash-flow ratio is 64.79 and its dividend yield is 0.5%.

**Analysts.** Of 46 ratings, 34 are buy, 9 hold and 3 sell, for a consensus of "Buy." Analysts' price targets average $1445.12, with a median of $1450.00, a high of $1650.00 and a low of $940.00. Several firms, including UBS, RBC Capital and Truist, reiterated positive ratings after the earnings report. One model is far more cautious: the FMP discounted cash flow model estimates $790.68 per share, a model output and not a forecast we endorse.

**Stock Expert AI MoonshotScore.** Lilly scores 98.1 (Exceptional). Among sector-relative pillars, growth is 100, quality 97, safety 93 and momentum 91, while valuation is just 35. The score rewards the growth and profitability and flags price as the weak spot.

**What could go wrong.** Management named several risks:
- Falling net prices.
- Some employers dropping coverage.
- An unsettled future for the Medicare Bridge pilot.
- Lower expected adherence to the oral drug than to injections.
- Restricted promotion in the UK until October due to MHRA pre-vetting requirements (per Patrik Jonsson).
- Higher discontinuations from adverse events at the higher dose of an experimental drug, which will be studied with slower dose increases.

On our side, valuation is the weak pillar, and the balance sheet carries total debt of $49.50B against cash and short-term investments of $4.88B, for net debt of $44.62B. Financial strength scores are solid (Piotroski 7 of 9, Altman Z 9.13). In the last 90 days of filings we checked, there were no open-market insider purchases and one sale.

## What to watch next

- **Fourth-quarter results:** our data provider lists Feb. 3, 2027, with an analyst EPS estimate of $11.2 and a revenue estimate of $24.58B. Management referred to its "Q4 call in January," where it said it will share 2027 guidance, so confirm the date with the company.
- **Hims & Hers rollout:** the release flags timing and integration risks. Watch whether management quantifies the channel's contribution.
- **Medicare Bridge:** whether the program continues beyond its pilot.
- **Margins:** whether the operating margin returns toward earlier levels once the up-front charges pass.

## Frequently asked questions

## Q: What is the Eli Lilly and Hims & Hers agreement?
Announced Nov. 6, 2026, it lets eligible patients with a provider's prescription on the Hims & Hers platform buy Lilly's Zepbound and Foundayo at Lilly's standard self-pay prices, shipped to their home. According to the release, Hims & Hers has never offered compounded copies of Lilly's GLP-1s and has committed not to in the future.

## Q: How did Eli Lilly (LLY) do in the third quarter of 2026?
In the quarter ended Sept. 30, 2026, Lilly reported revenue of $24.40B, up 38.6% from a year earlier, and net income of $6.45B, up 15.6%. Both revenue and non-GAAP EPS of $7.48 (GAAP diluted EPS was $7.22) beat analyst estimates. The operating margin was 35.3%, down from 54.2% in the previous quarter.

## Q: Is Eli Lilly stock expensive compared with other drugmakers?
On Nov. 6, 2026, Lilly's trailing P/E was 43.83, above Amgen (26.49) and AstraZeneca (26.11) and below AbbVie (49.97). Its net margin of 31.9% is the highest of those peers. Our MoonshotScore valuation pillar is 35, which is weak. This is a description of the data, not advice.

**What our data could not verify:** the financial terms of the Hims & Hers agreement, the exact causes of the operating-margin drop, and the segment comparison with the year-ago quarter, which the provider labels inconsistently.

**Sources:** Stock Expert AI data (FMP financials, consensus and MoonshotScore) as of Nov. 6, 2026; Lilly's Nov. 6, 2026 release and Oct. 29, 2026 earnings call, as reported by the company; third-party headlines used for context only.


*This is educational content, not investment advice. Past performance does not guarantee future results.*

## Related Tickers
- [LLY](https://www.stockexpertai.com/stock/lly)

## Sources
- [Stock Expert AI LLY page: quote, financials and MoonshotScore](https://www.stockexpertai.com/stock/lly)
- [prnewswire.com: Lilly and Hims & Hers expand access to FDA-approved Lilly medicines](https://www.prnewswire.com/news-releases/lilly-and-hims--hers-expand-access-to-fda-approved-lilly-medicines-302931979.html)
- [fool.com: Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence](https://www.fool.com/investing/2026/11/06/eli-lilly-is-much-more-than-a-weight-loss-drug-company-here-s-the-evidence/)
- [benzinga.com: Telehealth Giant Hims & Hers Partners with Eli Lilly for Direct Weight Loss Drug Delivery](https://www.benzinga.com/news/health-care/26/11/62996504/telehealth-giant-hims-hers-partners-with-eli-lilly-for-direct-weight-loss-drug-delivery)
- [investors.com: Top Funds Feast On Shell, Microsoft, Palantir And 24 More Stocks](https://www.investors.com/etfs-and-funds/mutual-funds/best-mutual-funds-feast-on-shell-microsoft-palantir-lilly-apple-and-more-stocks-to-watch/)

---
_Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article. Educational research, not financial advice._